MORGANTOWN, W.Va. – The WVU Cancer Institute has enrolled two of the first three patients in a national clinical trial for a novel breast cancer vaccine.
The trial, sponsored by the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, will examine the recommended biologic dose of a vaccine in combination with pembrolizumab, an immunotherapy drug that is used to fight certain cancers, in the treatment of patients with advanced triple-negative breast cancer.
“This vaccine works differently than traditional vaccines by helping to stimulate an immune response, which will enable the immunotherapy agent to uncloak and attack the cancer,” Sobha Kurian, M.D., WVU Medicine hematologist/oncologist and primary investigator of the study, said. “The immunotherapy by itself may not work against certain cancers because the cancer cells cloak themselves and often cannot be detected by the immune system, but this vaccine may help to overcome this problem.”
The WVU Cancer Institute joins 10 other cancer centers across the country in recruiting 29 patients for this study.
“The ability to participate in this study exemplifies the WVU Cancer Institute’s role as a leader in cancer research,” Dr. Kurian said. “The field of breast cancer research is constantly evolving, and we are honored to be at the forefront.”
Patients who receive the treatment will be closely monitored for up to 90 days to assess the efficacy of the drug and vaccine combination.
For more information on the WVU Cancer Institute, visit WVUMedicine.org/Cancer.
To date, the Norma Mae Huggins Cancer Research Endowment Fund has raised about $5 million to support clinical research trials for cancer patients in West Virginia. But, to the patients and physicians impacted by those funds, their value is priceless. To learn more, click here.
WVU Medicine Grateful Patients program provides $10K to help West Virginians plan for end-of-life care
The Grateful Patients, Families, and Friends program recently contributed $10,000 to ensure the West Virginia Center for End-of-Life Care can continue to provide free information, education and resources to help West Virginians document their wishes for medical care.
Chad Morley, M.D., WVU Medicine urologist, has been recognized for excellence in performing GreenLight™ laser therapy treatment – a minimally invasive outpatient procedure to treat benign prostatic hyperplasia (BPH), which can relieve bothersome voiding symptoms. Dr. Morley is the first urologist in the state to receive this honor.
Specialists from WVU Medicine Children’s are now providing appointments for families at WVU Medicine St. Joseph’s Hospital in Buckhannon.